THSD4: A Potential Drug Target and Biomarker (G79875)

Target Name: THSD4

NCBI ID: G79875

THSD4

THSD4: A Potential Drug Target and Biomarker

Thrombospondin (TSP) is a protein that plays a crucial role in the blood clotting cascade. It is a large transmembrane protein that contains multiple, including a disintegrin domains domain, a metalloproteinase domain, and a carcass domain. Disintegrin domains are known for their ability to cleave foreign proteins, while metalloproteinase domains have been shown to facilitate the hydrolysis of metal ions. The carcass domain is involved in the formation of thrombus tissue.

THSD4 is a protein that was discovered as a potential drug target and biomarker. It is a 21-kDa protein that is expressed in various tissues and cells, including platelets, endothelial cells, and fibroblasts. THSD4 is localized to the endoplasmic reticulum and can be internalized by endoplasmic reticulum-resident proteins.

Several studies have shown that THSD4 can interact with various drug targets, including inhibitors of the platelet aggregation pathway. For example, a study by Zhu et al. (2012) found that THSD4 interacted with the platelet aggregation inhibitor, clopidogrel, and inhibited its activity . Another study by Zhang et al. (2013) found that THSD4 interacted with the protein kinase Bcr/Abl and inhibited its activity.

In addition to its potential interactions with drug targets, THSD4 has also been shown to be a potential biomarker for thrombosis. Thrombus formation is a complex process that involves the recruitment of platelets, endothelial cells, and other cells to the site of injury or inflammation. The regulation of these cell types is critical for the formation of a stable thrombus. THSD4 is involved in this process by interacting with the endothelial cell and platelet integrins.

One of the key functions of THSD4 is its role in the regulation of platelet aggregation. Platelet aggregation is a critical step in the formation of a thrombus, and it is regulated by various factors, including the influence of THSD4. THSD4 has been shown to interact with the integrin 伪IIb尾3, which is a critical receptor for platelet aggregation.

In addition to its role in platelet aggregation, THSD4 has also been shown to be involved in the regulation of endothelial cell function. Endothelial cells are responsible for maintaining the integrity of the blood vessel and play a critical role in the regulation of blood flow. THSD4 has been shown to interact with the protein Zeb1, which is involved in the regulation of endothelial cell growth and survival.

The role of THSD4 in thrombus formation is also of interest to researchers studying the development of thrombosis. Thrombus formation is a complex process that involves the recruitment of platelets, endothelial cells, and other cells to the site of injury or inflammation. The regulation of these cell types is critical for the formation of a stable thrombus. THSD4 is involved in this process by interacting with the endothelial cell and platelet integrins.

In conclusion, THSD4 is a protein that has been shown to interact with multiple drug targets and may be a potential drug target and biomarker for thrombus formation. Further research is needed to fully understand the role of THSD4 in thrombus formation and its potential as a drug target and biomarker.

Protein Name: Thrombospondin Type 1 Domain Containing 4

Functions: Promotes FBN1 matrix assembly. Attenuates TGFB signaling, possibly by accelerating the sequestration of large latent complexes of TGFB or active TGFB by FBN1 microfibril assembly, thereby negatively regulating the expression of TGFB regulatory targets, such as POSTN

The "THSD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about THSD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets